PATENT CLAIM ANALYSIS

Application Number: 16002555
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "252120"]

Abstract:
Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

Claim (Index 19):
A method according to  claim 17 , wherein the cancer is prostate cancer.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 94.0
- Lexical Diversity: 1.2549
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10474778', '14911703', '12659124', '10384499', '11776476']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7691219038085917
- 35 USC 102 Novelty (BERT): 0.4922356600854139
- Combined Prediction Score: 0.7414332794362739
- Mean Citation Score: 234.986408
- Max Citation Score: 261.48654
- Similarity Product: 229.68225604539867

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test